Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence

Raed Alroughani 1, Samar Farouk Ahmed 2 3, Raed Behbehani 4, Jasem Al-Hashel 2 5

Affiliations

01 December 2017

-

doi: 10.1007/s40120-017-0080-x

Abstract

Introduction: Dimethyl fumarate (DMF) has been recently approved as a disease-modifying therapy for the treatment of multiple sclerosis (MS). Post-marketing studies are important to confirm what was established in clinical trials.

Objective: To evaluate effectiveness and safety of DMF and to measure the occurrence of lymphopenia in a cohort of MS patients in a clinical setting.

Methods: Using the national MS registry, we prospectively assessed relapsing MS patients who had been prescribed DMF for at least 6 months. Primary outcome measure was the proportion of relapse-free patients at last follow-up visit. Secondary outcome measures were the mean change in expanded disability status scale (EDSS) and the proportion of patients with radiological activity (gadolinium-enhancing or new T2 lesions) at the last follow-up visit. Absolute lymphocyte count (ALC) was assessed at baseline (within 6 months prior to DMF initiation) and at one or more times during DMF treatment 3 months post-initiation.

Results: Of 134 patients identified, 119 were eligible and included in the analysis. Women represented 59.7% of the studied cohort. Mean age and mean disease duration were 33.5 ± 11.1 and 8.3 ± 7 years, respectively. A total of 75.6% of the patients received prior disease-modifying therapies. Mean duration of DMF exposure was 20.5 ± 9.5 months. The proportion of relapse-free patients increased significantly from 51.2% to 89.9% (p < 0.0001), while the mean EDSS score decreased from 2.8 ± 1.8 at baseline to 2.3 ± 1.7 (p < 0.058) at last follow-up visit. The proportion of patients with MRI activity decreased significantly from 61.1% to 15.1% (p < 0.0001). The mean ALCs decreased from 2170 to 1430 cells/μl (34% decrease). Lymphopenia was seen in 13 (10.9%) patients, of whom 3 (2.5%) patients had grade 3 lymphopenia necessitating discontinuation of DMF. Although no serious adverse events were reported, 19.3% of patients discontinued DMF.

Conclusion: In clinical practice, DMF appeared to be effective in reducing disease activity and progression of disability throughout the observational period. DMF was well tolerated with no serious adverse events. ALC profiles in DMF-treated patients were generally stable throughout the observational period. The proportion of patients who developed severe lymphopenia was similar to figures in clinical trials.

Keywords: Dimethyl fumarate; Kuwait; Lymphopenia; Multiple sclerosis; Safety.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care. 2013;19:S15–S20. - PubMed
  2.  
    1. FDA. Prescribing information: TECFIDERA. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204063lbl.pdf. Accessed June 12, 2017.
  3.  
    1. Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012;341:274–284. doi: 10.1124/jpet.111.190132. - DOI - PubMed
  4.  
    1. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372:1463–1472. doi: 10.1016/S0140-6736(08)61619-0. - DOI - PubMed
  5.  
    1. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–1097. doi: 10.1056/NEJMoa1206328. - DOI - PubMed
  6.  
    1. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–1107. doi: 10.1056/NEJMoa1114287. - DOI - PubMed
  7.  
    1. Alroughani R, Ahmed SF, Behbahani R, et al. Increasing prevalence and incidence rates of multiple sclerosis in Kuwait. Mult Scler. 2014;20:543–547. doi: 10.1177/1352458513504328. - DOI - PubMed
  8.  
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology. 1983;33:1444–1452. doi: 10.1212/WNL.33.11.1444. - DOI - PubMed
  9.  
    1. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61:1528–1532. doi: 10.1212/01.WNL.0000096175.39831.21. - DOI - PubMed
  10.  
    1. Publication N. National Cancer Institute. Common terminology criteria for adverse events. 2009;4: #09–7473.
  11.  
    1. Smoot K, Spinelli KJ, Stuchiner T, et al. Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center. Mult Scler. 2017. doi:10.1177/1352458517709956. - PubMed
  12.  
    1. Miclea A, Leussink VI, Hartung HP, Gold R, Hoepner R. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. J Neurol. 2016;263:1626–1632. doi: 10.1007/s00415-016-8175-3. - DOI - PubMed
  13.  
    1. Lee P, Plavina T, Castro A, et al. A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol. 2013;57:141–146. doi: 10.1016/j.jcv.2013.02.002. - DOI - PubMed
  14.  
    1. Melis M, Cocco E, Frau J, et al. Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up. Neurol Sci. 2014;35:401–408. doi: 10.1007/s10072-013-1527-1. - DOI - PubMed
  15.  
    1. Lo Re M, Capobianco M, Ragonese P, et al. Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers. Neurol Ther. 2015;4:147–157. doi: 10.1007/s40120-015-0038-9. - DOI - PMC - PubMed
  16.  
    1. Vidal-Jordana A, Tintore M, Tur C, et al. Significant clinical worsening after natalizumab withdrawal: predictive factors. Mult Scler. 2015;21:780–785. doi: 10.1177/1352458514549401. - DOI - PubMed
  17.  
    1. de Seze J, Ongagna JC, Collongues N, et al. Reduction of the washout time between natalizumab and fingolimod. Mult Scler. 2013;19:1248. doi: 10.1177/1352458513490551. - DOI - PubMed
  18.  
    1. Jokubaitis VG, Li V, Kalincik T, et al. Fingolimod after natalizumab and the risk of short-term relapse. Neurology. 2014;82:1204–1211. doi: 10.1212/WNL.0000000000000283. - DOI - PMC - PubMed
  19.  
    1. Kerbrat A, Le Page E, Leray E, et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci. 2011;308:98–102. doi: 10.1016/j.jns.2011.05.043. - DOI - PubMed
  20.  
    1. Zurawski J, Flinn A, Sklover L, Sloane JA. Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors. J Neurol. 2016;263:1511–1517. doi: 10.1007/s00415-016-8162-8. - DOI - PubMed
  21.  
    1. Patti F, Leone C, Zappia M. Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report. BMC Neurol. 2015;15:252. doi: 10.1186/s12883-015-0512-0. - DOI - PMC - PubMed
  22.  
    1. Cocco E, Sardu C, Spinicci G, et al. Influence of treatments in multiple sclerosis disability: a cohort study. Mult Scler. 2015;21:433–441. doi: 10.1177/1352458514546788. - DOI - PubMed
  23.  
    1. Fox EJ, Vasquez A, Grainger W, et al. Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE) Int J MS Care. 2016;18:9–18. doi: 10.7224/1537-2073.2014-101. - DOI - PMC - PubMed
  24.  
    1. Berkovich R, Weiner LP. Effects of dimethyl fumarate on lymphocyte subsets. Mult Scler Relat Disord. 2015;4:339–341. doi: 10.1016/j.msard.2015.06.002. - DOI - PubMed
  25.  
    1. Khatri BO, Garland J, Berger J, et al. The effect of dimethyl fumarate (Tecfidera) on lymphocyte counts: a potential contributor to progressive multifocal leukoencephalopathy risk. Mult Scler Relat Disord. 2015;4:377–379. doi: 10.1016/j.msard.2015.05.003. - DOI - PubMed
  26.  
    1. Longbrake EE, Cross AH. Dimethyl fumarate associated lymphopenia in clinical practice. Mult Scler. 2015;21:796–797. doi: 10.1177/1352458514559299. - DOI - PMC - PubMed
  27.  
    1. Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003;121:1383–1388. doi: 10.1111/j.1523-1747.2003.12605.x. - DOI - PubMed

Page Navigation